Article Text

other Versions

PDF
Research paper
Cerebral tau is elevated after aneurysmal subarachnoid haemorrhage and associated with brain metabolic distress and poor functional and cognitive long-term outcome
  1. Raimund Helbok1,
  2. Alois Schiefecker1,
  3. Margarete Delazer1,
  4. Ronny Beer1,
  5. Thomas Bodner1,
  6. Bettina Pfausler1,
  7. Thomas Benke1,
  8. Peter Lackner1,
  9. Marlene Fischer1,
  10. Florian Sohm2,
  11. Werner Hackl3,
  12. John F Stover4,
  13. Claudius Thomé2,
  14. Christian Humpel5,
  15. Erich Schmutzhard1
  1. 1Department of Neurology, Innsbruck Medical University, Innsbruck, Austria
  2. 2Department of Neurosurgery, Innsbruck Medical University, Innsbruck, Austria
  3. 3UMIT—University for Health Sciences, Medical Informatics and Technology, Hall, Austria
  4. 4Fresenius Kabi, Bad Homburg, Germany
  5. 5Department of Psychiatry and Psychotherapy, Innsbruck Medical University, Innsbruck, Austria
  1. Correspondence to Dr Raimund Helbok, Department of Neurology, Innsbruck Medical University, Anichstrasse 35, 6020 Innsbruck, Austria; raimund.helbok{at}uki.at

Abstract

Background Recent evidence suggests axonal injury after aneurysmal subarachnoid haemorrhage (aSAH). The microtubule-associated protein, tau, has been shown to be elevated in the cerebrospinal fluid after aSAH, however, brain extracellular tau levels and their relation to long-term neurological and cognitive outcomes have not been investigated.

Methods Serial cerebral microdialysis (CMD) samples were collected from 22 consecutive aSAH patients with multimodal neuromonitoring to determine CMD-total-tau by ELISA. CMD-total-tau was analysed considering other brain metabolic parameters, brain tissue oxygen tension (PbtO2), and functional and neuropsychological outcome at 12 months. All outcome models were analysed using generalised estimating equations with an autoregressive working correlation matrix to account for multiple measurements of brain extracellular proteins per subject.

Results CMD-total-tau levels positively correlated with brain extracellular fluid levels of lactate (r=0.40, p<0.001), glutamate (r=0.45, p<0.001), pyruvate (r=0.26, p<0.001), and the lactate-pyruvate ratio (r=0.26, p<0.001), and were higher in episodes of hypoxic (PbtO2<20 mm Hg) brain extracellular lactate elevation (>4 mmol/L) (p<0.01). More importantly, high CMD-total-tau levels were associated with poor functional outcome (modified Rankin Scale ≥4) 12 months after aSAH even after adjusting for disease severity and age (p=0.001). A similar association was found with 3/5 neuropsychological tests indicative of impairments in cognition, psychomotor speed, visual conceptualisation and frontal executive functions at 1 year after aSAH (p<0.01).

Conclusions These results suggest that CMD-total tau may be an important biomarker for predicting long-term outcome in patients with severe aSAH. The value of axonal injury needs further confirmation in a larger patient cohort, preferably combined with advanced imaging techniques.

  • Subarachnoid Haemorrhage
  • Intensive Care
  • Cerebrovascular Disease

Statistics from Altmetric.com

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.